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Western lowland gorillas (Gorilla gorilla gorilla) are infected with a simian immunodeficiency virus (SIVgor)
that is closely related to chimpanzee and human immunodeficiency viruses (SIVcpz and HIV-1, respectively)
in west central Africa. Although existing data suggest a chimpanzee origin for SIVgor, a paucity of available
sequences has precluded definitive conclusions. Here, we report the molecular characterization of one partial
(BQ664) and three full-length (CP684, CP2135, and CP2139) SIVgor genomes amplified from fecal RNAs of
wild-living gorillas at two field sites in Cameroon. Phylogenetic analyses showed that all SIVgor strains
clustered together, forming a monophyletic lineage throughout their genomes. Interestingly, the closest rela-
tives of SIVgor were not SIVcpzPtt strains from west central African chimpanzees (Pan troglodytes troglodytes)
but human viruses belonging to HIV-1 group O. In trees derived from most genomic regions, SIVgor and HIV-1
group O formed a sister clade to the SIVcpzPtt lineage. However, in a tree derived from 5 pol sequences (900
bp), SIVgor and HIV-1 group O fell within the SIVcpzPtt radiation. The latter was due to two SIVcpzPtt strains
that contained mosaic pol sequences, pointing to the existence of a divergent SIVcpzPtt lineage that gave rise
to SIVgor and HIV-1 group O. Gorillas appear to have acquired this lineage at least 100 to 200 years ago. To
examine the biological properties of SIVgor, we synthesized a full-length provirus from fecal consensus
sequences. Transfection of the resulting clone (CP2139.287) into 293T cells yielded infectious virus that
replicated efficiently in both human and chimpanzee CD4 T cells and used CCR5 as the coreceptor for viral
entry. Together, these results provide strong evidence that P. t. troglodytes apes were the source of SIVgor. These
same apes may also have spawned the group O epidemic; however, the possibility that gorillas served as an
intermediary host cannot be excluded.
Simian immunodeficiency viruses (SIVs) are known to nat-
urally infect at least 40 different species of nonhuman primates
in Sub-Saharan Africa (9, 72). Although each of these primate
species harbors a genetically distinct lineage of SIV, phyloge-
netic evidence indicates that SIVs have crossed species bound-
aries on numerous occasions in the past (5, 6, 30, 57). Until
recently, SIV cross-species transmissions could be detected
only by analyzing blood samples coincident with the capture or
killing of primates (10, 32, 73). However, the development of
noninvasive viral detection methods has transformed the way
infectious agents, including SIV, can be studied in wild-living
primate populations (33, 38, 51–54, 70). For example, system-
atic testing of fecal samples from wild-living chimpanzees (Pan
troglodytes) for viral nucleic acids and antibodies traced the
origin of pandemic (group M) and nonpandemic (group N)
human immunodeficiency virus type 1 (HIV-1) to distinct
chimpanzee communities in south-central and southeastern
Cameroon, respectively (33). Noninvasive surveys also uncov-
ered a new SIV lineage in wild-living gorillas (Gorilla gorilla)
(71). An analysis of 213 gorilla fecal samples from 11 field sites
in Cameroon revealed three individuals that were SIV/HIV
antibody positive (71). PCR amplification of viral sequences
from fecal RNA confirmed infection by distinct SIV strains
which comprised a new lineage, termed SIVgor. In phyloge-
netic trees of diagnostic pol and env sequences, the new gorilla
viruses fell within the SIVcpz radiation and were most closely
related to HIV-1 group O (71). These findings suggested that
gorillas, like humans, had acquired SIV from chimpanzees;
however, the paucity of available SIVgor sequences precluded
definitive conclusions regarding the origins of SIVgor or
HIV-1 group O.
Gorillas are classified into two species, with habitats in west
central (Gorilla gorilla) and east (Gorilla beringei) Africa, re-
spectively (Fig. 1). The western species is further subdivided
into the Cross River gorilla (Gorilla gorilla diehli) and the
western lowland gorilla (Gorilla gorilla gorilla), while the east-
ern species includes the mountain gorilla (Gorilla beringei
beringei), Grauer’s gorilla (Gorilla beringei graueri), and possi-
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bly the Bwindi gorilla (a G. beringei subspecies of uncertain
classification) (16). Both western subspecies have been
screened for SIVgor infection, but only western lowland goril-
las were found to harbor this virus (71). Moreover, SIVgor
infection appears to be rare. Initially, only three gorillas from
field sites in southwestern (CP) and south-central (BQ) Cam-
eroon were found to be SIV positive (Fig. 1). Subsequent
analyses have uncovered eight additional SIVgor infections (C.
Neel and M. Peeters, unpublished); however, all of these were
identified at one of the two field sites (CP) where SIVgor was
first discovered. Thus, there are currently only two locations in
Cameroon where SIVgor infection has been documented. The
fact that these two sites are 400 km apart raises the question of
whether gorillas acquire SIV sporadically from local sources or
whether the currently known viruses all resulted from a single
cross-species transmission event.
The finding of SIV in wild-living gorillas came as a surprise
and raised a number of issues. First, unlike for other primate
lentiviruses that were first identified in captive primates, there
was no prior evidence of SIV infection in captive gorillas.
Second, the route by which gorillas could have acquired SIV
was not immediately obvious. Gorillas are herbivorous and
believed to avoid physical interaction with other primates (41,
60, 67). In contrast, chimpanzees are avid hunters that prey on
smaller monkeys (13, 29, 40, 61). Thus, while chimpanzees
likely acquired SIV through predation (6, 57), this mode of
transmission is improbable for SIVgor. Third, the range of
western lowland gorillas (G. g. gorilla) overlaps that of central
chimpanzees (Pan troglodytes troglodytes) (Fig. 1), and SIVgor
is significantly more closely related to SIVcpzPtt from the cen-
tral subspecies than it is to SIVcpzPts from eastern chimpan-
zees (Pan troglodytes schweinfurthii) (71). These data would
suggest that central chimpanzees transmitted their virus to
sympatric gorillas, albeit by an as-yet-unknown route. How-
ever, under such a scenario, gorilla viruses might be expected
to fall within the radiation of SIVcpzPtt strains in evolutionary
trees, which is not the case (71). Finally, given that gorillas
acquired a chimpanzee SIV (71), one could ask whether this
has occurred only once and only in west central Africa. As
shown in Fig. 1, eastern chimpanzees and gorillas also live in
sympatry, thus providing potential transmission opportunities.
Given these uncertainties, it is clear that additional chimpan-
zee and gorilla viruses need to be analyzed to elucidate the
ancestry of SIVgor.
In the present study, we sought to gain new insight into
the evolutionary origin of SIVgor and to begin to probe its
biological properties. To accomplish this, we amplified par-
tial (BQ664) and full-length (CP684, CP2135, and CP2139)
genomes from fecal samples previously shown to contain
SIVgor-specific viral RNA. We then performed analyses to (i)
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FIG. 1. Locations of gorilla and chimpanzee subspecies in west central and east Africa. The natural ranges of western gorillas (Gorilla gorilla,
solid green) and eastern gorillas (Gorilla beringei, solid magenta) are shown in relation to the ranges of sympatric central chimpanzees (P. t.
troglodytes, hatched green) and eastern chimpanzees (P. t. schweinfurthii, hatched magenta) (16). The western gorilla species is subdivided into the
Cross River gorilla (G. g. diehli) on the Cameroonian/Nigerian border and the western lowland gorilla (G. g. gorilla) in southern Cameroon, Gabon,
Equatorial Guinea, the Republic of Congo, and the Central African Republic. The eastern species is classified into Grauer’s gorilla (G. b. graueri)
in the Democratic Republic of the Congo; the mountain gorilla (G. b. beringei) on the border of the Democratic Republic of the Congo, Rwanda,
and Uganda; and the Bwindi gorilla (a G. beringei subspecies) in Uganda (the classification of the last is still uncertain). The locations of two study
sites (CP and BQ) are indicated. International borders (black lines) and major rivers (blue lines) are also shown.
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characterize the phylogenetic relationships of SIVgor over the
entire length of its genome, (ii) investigate whether SIVgor has
undergone recombination, (iii) identify the primate reservoir
that gave rise to SIVgor, (iv) examine the possibility of local
chimpanzee-to-gorilla SIV transmission, and (v) generate the
first replication-competent molecular clone of SIVgor for bio-
logical characterization. Our results strongly suggest that go-
rillas acquired SIVcpzPtt from P. t. troglodytes apes and that the
current SIVgor lineage is the result of a single such cross-
species transmission event. Although it is still unclear whether
chimpanzees or gorillas were the source of HIV-1 group O, in
vitro studies demonstrate that SIVgor has many of the biolog-
ical properties necessary for establishing a persistent infection
in humans.
MATERIALS AND METHODS
Ape fecal samples. To amplify full-length SIVgor genomes, fecal samples
representing four naturally infected (female) western lowland gorillas were se-
lected for analysis. These included samples CP684 (collected on 18 April 2004)
and BQ664 (9 August 2004), which were previously reported to contain SIVgor
viral RNA (71), as well as samples CP2135 (11 February 2007) and CP2139 (11
February 2007), which were identified to contain SIVgor-specific antibodies
during a follow-up study at the CP field site (C. Neel and M. Peeters, unpub-
lished). We also selected two fecal samples from wild chimpanzees at the CP field
site for molecular characterization. Both CP1973 (17 December 2006) and
CP2680 (28 August 2007) contained SIVcpz-specific antibodies and represented
two female P. t. troglodytes apes, as determined by mitochondrial DNA, micro-
satellite, and sex marker analyses as described previously (33).
Amplification of SIVgor sequences. For samples CP2135, CP2139, and CP684,
full-length SIVgor sequences were generated by amplifying partially overlapping
subgenomic fragments (339 bp to 1,608 bp in length) from fecal virion RNA. For
sample BQ664, only gag (1,126 bp) and vif-env (963 bp) sequences were ampli-
fied. Reverse transcriptase PCR (RT-PCR) analysis was performed as described
previously (33, 51, 52, 65, 71), with some modifications. For CP684, 10 l of RNA
was first incubated with 40 pmol of the outer reverse primer (1 l) for 10 min at
65°C, rapidly cooled on ice, and then added to the remaining components in a
20-l reaction volume containing 1 Expand reverse transcriptase buffer, 1 mM
deoxynucleoside triphosphate (dNTP), 5 mM dithiothreitol, 1 unit (U)/l RNase
inhibitor (Ambion, Austin, TX), and 2.5 U/l Expand reverse transcriptase
(Roche Diagnostics, Indianapolis, IN). This reaction mixture was incubated for
60 min at 42°C and heat inactivated at 95°C for 2 min, and 10 l was used for
PCR. For CP2135 and CP2139, cDNA was synthesized in a 20-l reaction
volume containing 10 l fecal RNA, 1 reaction buffer, 20 U of RNase inhibitor
(Ambion, Austin, TX), 0.5 mM dNTP, 5 mM dithiothreitol, 2 pmol outer reverse
primer, and 200 U of SuperScript III reverse transcriptase (Invitrogen, Carlsbad,
CA). The reaction mixture was incubated at 50°C for 90 min and, after addition
of another 200 U of enzyme, for an additional 90 min at 55°C. Following heat
inactivation of the enzyme at 70°C for 15 min, 7 l cDNA was then added to a
PCR mixture containing 1 Expand buffer 2, 0.5 mM dNTP, 300 nM of first-
round PCR primers, 25 g bovine serum albumin, and 3.75 U of Expand Long
Template enzyme mixture (Roche Diagnostics, Indianapolis, IN). Different com-
binations of consensus sequence- and strain-specific primers were used to am-
plify between 8 and 15 subgenomic fragments per proviral genome (Fig. 2);
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FIG. 2. Generation of a replication-competent SIVgor clone. (A) The positions of individual RT-PCR products (open boxes) are shown in
relation to the SIVgor provirus. Previously reported BQ664 amplicons are hatched (71). All fragments are drawn to scale, and the length of the
assembled population sequence is indicated. Nucleotide sequences are numbered starting at the beginning of the R region in the 5 LTR (see scale
bar). (B) The CP2139 genome was amplified on an independent occasion, using strain-specific primers designed to amplify larger fragments. The
resulting second consensus sequence (CP2139.2) differed from the first consensus sequence (CP2139.1) at 54 positions (see Table S3 in the
supplemental material). One nucleotide was selected at each of these sites and the resulting master consensus sequence synthesized as three
adjoining fragments (schematic on the bottom). Unique restriction enzyme sites allowed directional cloning into a low-copy-number plasmid vector
(pBR322-MCS).
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primer sequences and corresponding fragment lengths are listed in Table S1 in
the supplemental material. The amplification conditions for first- and second-
round PCR included 35 cycles of denaturation (94°C, 0.5 min), annealing (55°C,
0.5 min), and extension (68°C, 1 min). Amplicons were gel purified and se-
quenced directly using an ABI 3730 DNA analyzer. Chromatograms were ex-
amined for positions of base mixtures by using Sequencher version 4.7 (Gene
Codes Corporation, Ann Arbor, MI) or Lasergene Seqman Pro version 7.1.0
(DNASTAR, Inc., Madison, WI). In addition, nucleotide differences between
adjoining fragments in regions of sequence overlap were recorded (see Table S2
in the supplemental material). The genome of CP2139 was amplified twice (Fig.
2), the first time using a combination of consensus sequence- and strain-specific
primers (CP2139.1) and the second time using only strain-specific primers de-
signed to generate larger fragments (CP2139.2). Consensus sequences from
these two amplifications were then used to generate a master consensus se-
quence (see Table S3 in the supplemental material), which served as the tem-
plate to generate a full-length SIVgor molecular clone.
Amplification of SIVcpz sequences. For samples CP1973 and CP2680, a highly
conserved SIVcpz pol fragment (220 bp) was amplified, using degenerate HIV-
1/SIVcpz/SIVgor consensus primers (F1, 5-CATGTRGCHAGTGGNTWCMT
AGARGCAGARGT-3; R1, 5-ACBACYGCNCCTTCHCCTTTC-3; F2, 5-A
YAAYCCHCAAAGTCAAGGAGTRGT-3; and R2, 5-GTCCTTTCCAAAT
DGGRTCTCTGCTGTC-3). The amplification conditions for both first- and
second-round PCR included 35 cycles of denaturation (94°C, 0.25 min), anneal-
ing (55°C, 0.5 min), and extension (68°C, 0.5 min).
Construction of a full-length SIVgor clone. To obtain a full-length infectious
molecular clone of SIVgor, the CP2139 master consensus sequence was used as
a template to chemically synthesize three subgenomic fragments (Blue Heron
Biotechnology, Bothell, WA), spanning the 5 long terminal repeat (LTR)-pol
(4.2 kb), pol-env (3.0 kb), and env-3 LTR (2.6 kb) regions (Fig. 2B). To facilitate
subsequent cloning, unique MluI and NotI sites were added to the 5 and 3
termini of the provirus, respectively (Fig. 2B). These, together with internal KpnI
and ApaI sites at positions 4171 and 7208, were then used to assemble the three
subgenomic fragments to generate a full-length provirus. To accomplish this,
individual fragments were first cloned into in a low-copy-number plasmid vector
(pBR-MCS), which was engineered by ligating a synthetic polylinker containing
an MluI-KpnI-XhoI-ApaI-NotI multicloning site (consisting of complementary
oligonucleotide sequences 5-AATTCACGCGTGGTACCTCGAGGGCCCGC
GGCCGCA-3 and 5-AGCTTGCGGCCGCGGGCCCTCGAGGTACCACG
CGTG-3) into pBR322 digested with EcoRI and HindIII. The 4.2-kb fragment
was cloned into the MluI and KpnI sites of pBR-MCS. Following digestion of this
plasmid with KpnI and NotI, both 3.0-kb KpnI-ApaI and 2.6-kb ApaI-NotI
fragments were simultaneously ligated to generate a full-length proviral clone.
Transformation of XL2-MRF bacteria (Stratagene, La Jolla, CA) initially
yielded only defective clones containing either single-nucleotide substitutions or
larger insertions/deletions. One clone contained an 150-bp insert at the ApaI
site in its env gene. Since the sequence of this clone was otherwise identical to the
CP2139 master consensus sequence, it was digested with ApaI and recircularized.
Resulting XL2-MRF transformants were screened for appropriately sized in-
serts, transfected into 293T cells, and tested for infectivity in the JC53-BL assay
(21, 77). One functional clone (pBR-CP2139.287) was identified and grown large
scale.
Large-scale plasmid preparation. The pBR-CP2139.287 clone containing the
full-length SIVgor genome was propagated in XL2-MRF cells (Stratagene) at
30°C in a Forma orbital benchtop shaker (model 420/2l), using 500 ml LB
containing 100 g/ml ampicillin in 2-liter disposable Erlenmeyer flasks (16-cm
diameter, vented caps; Corning) at low levels of agitation (225 rounds per
minute). Bacterial cultures were harvested prior to reaching saturating growth
density and purified to be endotoxin free (Qiagen, Valencia, CA). Due to the
extreme instability of this clone in bacteria, all large-scale plasmid preparations
were sequence confirmed. The replication-competent pBR-CP2139.287 clone
has been submitted to the National Institutes of Health Research and Reference
Program (Rockville, MD).
Phylogenetic methods. Newly derived full-length SIVgor sequences were
translated and compared to previously published full-length HIV-1 and SIVcpz
sequences from the database as follows: for HIV-1 group M subtype A, U455A
(GenBank accession numbers are listed in Table S4 in the supplemental mate-
rial); for subtype B, HXB2; for group N, YBF30 and YBF106; for group O,
MVP5180 and ANT70; for SIVcpzPtt, MB897, DP943, LB7, MB66, EK505,
MT145, CAM3, CAM5, CAM13, GAB1, GAB2, and US; and for SIVcpzPts,
ANT, TAN1, TAN2, and TAN3. Amino acid sequences were aligned using
CLUSTAL W (66). Sites that could not be aligned unambiguously and sites with
a gap in any sequence were discarded. In regions of gene overlap (e.g., Gag/Pol
and Pol/Vif genes), the carboxy termini of the overlapping protein sequences
were discarded. Trees were inferred by the Bayesian Markov Chain/Monte Carlo
method of phylogenetic estimation (79), implemented in MrBayes version 3.1
(50) by using the mixed model of amino acid evolution with gamma-distributed
rates at sites and 1 million generations with 25% burn in. Average standard
deviations of split frequencies were 0.01 or lower. Four major regions of the
proteome were analyzed: Gag, Pol1, Pol2, and Env. The Pol sequence was
divided at the position of a recombination breakpoint previously identified in
HIV-1 group N (26). Trees of partial pol sequences for SIVcpzPtt strains CP1973
and CP2680 were inferred as described above from an alignment of 67 amino
acids, using 10 million generations in MrBayes.
To calculate the time to the most recent common ancestor (MRCA) of the
SIVgor clade, regions of an HIV-1/SIVcpz/SIVgor nucleotide sequence align-
ment corresponding to available BQ664 sequences were concatenated (total
length, 2,952 nucleotides). This alignment included new and previously published
BQ664 sequences (see Table S4 in the supplemental material), sequences listed
above, and additional sequences from HIV-1 group M: for ETH2220 (subtype
C), ELI (D) and 02CM.0016BBY (F2); for HIV-1 group N, 04CM-1015-04,
04CM-1131-03, and DJO131; and for HIV-1 group O, SEMP1299, SEMP1300,
and VAU. A maximum-likelihood phylogenetic tree was constructed with
PAUP* version 4.0b10 (64), using a general time-reversible model with gamma-
distributed site-to-site rate variation allowing for invariable sites (GTRIG
model), with parameters selected using MODELTEST version 3.7 (44, 45) and
the Akaike information criterion (2). Relevant branch lengths from the tree were
summed to provide the genetic distance of each HIV-1 group O strain from the
MRCA of this group. The evolutionary rate for each strain was calculated using
its date of isolation and the previously estimated date of the MRCA of group O
(35). The average of these rates was then used to estimate the time to the
common ancestor of the SIVgor sequences sampled here, again using distances
from summed branch lengths and taking account of dates of virus isolation.
For the analysis of SIVgor V3-loop sequences, a phenetic dendrogram was
estimated using the unweighted-pair group method with average linkages from a
distance matrix of uncorrected sequence differences, using NEIGHBOR from
PHYLIP version 3.64 (24). The following additional V3 sequences were in-
cluded: for HIV-1 group M, A1 92UG037 (see Table S4 in the supplemental
material), 97CDKTB48 (subtype A2), BK132 (B), ETH2220 (C), 94UG114 (D),
CM240 (01-AE), VI850 (F1), 02CM.0016BBY (F2), DRCBL (G), VI991 (H),
and EQTB11C (K); for SIVcpzPtt, BM1034, LB714, LB715, MB801, MB802,
MB776, MB803, DP935, and SL995; and for HIV-1 group O, SEMP1300 (O1),
97US08692A (O2), 96CMABB637 (O3), ANT70 (O4), and MVP5180 (O5).
To test for recombination among the SIVcpz ancestors of HIV-1 groups M, N,
and O and SIVgor, phylogenetic trees were examined across a concatenated Gag
and Pol alignment in windows of 300 residues moved in steps of 5 to 100 amino
acids (larger step sizes were used to screen for recombination; smaller step sizes
were used to map recombination breakpoints). To test for recombination among
the three newly derived SIVgor isolates, full-length nucleotide sequences of the
three SIVgor genomes were aligned and tested using GENECONV (http://
www.math.wusll.edu/sawyer).
Viral infectivity, coreceptor usage, and neutralization phenotype analyses.
Full-length molecular clones of SIVgor, SIVcpz, and HIV-1 were transfected
into 293T cells and supernatants equilibrated by particle-associated reverse
transcriptase activity as described previously (65). These included the SIVcpzPts
clones TAN1, TAN2, and TAN3 (65); the SIVcpzPtt clones GAB2 (11), MT145,
MB897, and EK505 (J. Decker and B. H. Hahn, unpublished); and the HIV-1
clones SG3 (28), NL4-3 (1), YU2 (37), and WEAU1.6 (18). In addition, human
peripheral blood mononuclear cell (PBMC)-derived viral isolates YBF30 (58)
and 97US08692A (78) were also used. Viral infectivity was assessed for
JC53BL-13 cells (TZM-bl; NIH AIDS Research and Reference Reagent Pro-
gram catalogue no. 8129), a HeLa-derived line which has been genetically mod-
ified to constitutively express CD4, CCR5, and CXCR4 and to contain integrated
luciferase and -galactosidase reporter genes under the control of an HIV-1
LTR (21, 77). For coreceptor analysis, JC53-BL cells were seeded in 96-well
plates at 8,300 cells/well overnight and then treated with the CCR5 antagonist
TAK-779 (10 mM) (4), the CXCR4 antagonist AMD3100 (1.2 mM) (20), or a
combination of both for 1 hour (NIH AIDS Research and Reference Reagent
Program catalogue no. 4983 and 8128, respectively). Virus was added in the
presence of 40 g/ml DEAE-dextran and removed 48 h later. Cells were then
lysed and analyzed for luciferase activity (Promega, Madison, WI), using a Tropix
luminometer with WinGlow version 1.24 software.
For neutralization assays, 3,000 infectious units of virus were combined in a
total volume of 60 l with or without a 2 concentration of sCD4 in Dulbecco’s
modified Eagle’s medium (DMEM) with 6% fetal calf serum (FCS) and 80 g/ml
DEAE-dextran. After 1 h at 37°C, an equal volume of human plasma (10%
[vol/vol] in DMEM plus 6% FCS or fivefold dilutions thereof), monoclonal
1638 TAKEHISA ET AL. J. VIROL.
antibodies, or fusion inhibitor was added. Monoclonal antibodies described in
reference 12 were kindly provided by the following individuals: Dennis Burton
(b12 and 2G12), Michael Zwick and Dennis Burton (Z13e1), Herman Katinger
(2F5 and 4E10), Susan Zolla-Pazner (447-52D), Lisa Cavacini (F425-B4e8),
James Robinson (17b, 19e, and 21c), and David Montefiori (HIVIG). The
following reagents were obtained commercially: soluble CD4 (514-CD; R&D
Systems), T1249 (Triangle Pharmaceuticals), and anti-CD4 monoclonal antibody
(catalogue no. 555344, clone RPA-T4; BD Pharmingen). The addition of ligand
or antibody brought the final concentration of DEAE dextran to 40 g/ml. Virus
was incubated with test antibodies (with or without sCD4) for 1 h at 37°C and
then added to JC53-BL cells. Cells were incubated at 37°C for 2 days and then
analyzed for luciferase expression. Controls included cells exposed to no virus or
to virus pretreated with normal human plasma. Relative infectivity was calcu-
lated by dividing the number of luciferase units at each dilution of test plasma or
monoclonal antibodies by values in wells containing normal human plasma.
Neutralization was assessed by 50% inhibitory concentration (IC50) determined
by linear regression using a least-squares method. All samples were tested in
duplicate.
Chimpanzee and human PBMC cultures. Blood was obtained from normal
human volunteers (Research Blood Components, Boston, MA) as well as healthy
(HIV-1-uninfected) chimpanzees housed at the Yerkes Regional Primate Center
as described previously (65). Briefly, PBMCs were isolated using Ficoll Hypaque
Plus (GE Healthcare, Piscataway, NJ). CD4 T cells were enriched using CD4
microbeads and magnetic cell sorting (Militenyi Biotec, Auburn, CA), stimulated
with staphylococcal enterotoxin B (Sigma-Aldridge, St. Louis, MO) for 12 to 15 h
(3 g/ml), and subsequently cocultivated with autologous monocyte-derived
macrophages for optimal activation. After 5 to 6 days, CD4 T cells were
removed from the macrophages, placed into DMEM with 10% FCS, and incu-
bated with 30 U/ml interleukin-2 (IL-2). After 24 h, 5  105 CD4 T cells were
incubated with transfection-derived viral stocks at a multiplicity of infection of
0.1 (as determined for JC53-BL cells) in 300 l DMEM containing 10% FCS and
30 U/ml IL-2 for 16 h. CD4 T cells were washed three times and plated in
24-well plates in DMEM with 10% FCS and 30 U/ml IL-2, and reverse trans-
criptase activity in culture supernatants was measured every 3 days to monitor
viral replication.
Nucleotide sequence accession numbers. The GenBank accession numbers for
the sequences determined in this study are FJ424871 (CP684 consensus se-
quence), FJ424863 (CP2135 consensus sequence), FJ424864 (CP2139.1 consen-
sus sequence), FJ424865 (CP2139.2 consensus sequence), FJ424866 (pBR-
CP2139.287), FJ424867 (BQ664 vif-env), FJ424868 (BQ664 gag), FJ424869
(CP1973 pol), and FJ424870 (CP2680 pol).
RESULTS
SIVgor genome structure. To amplify complete SIVgor ge-
nomes, we selected fecal samples from four infected western
lowland gorillas, all of which were sampled in the wild. Two of
these (CP684 and BQ664) were previously shown to harbor
divergent SIVgor strains based on subgenomic pol and gp41
sequences (71). The other two (CP2135 and CP2139) were
identified more recently, in a follow-up study of gorilla com-
munities at the CP field site (C. Neel and M. Peeters, unpub-
lished). All samples were positive for SIVgor antibodies, and
their species origins were determined by mitochondrial DNA
analysis. All samples were also shown to represent different
individuals, based on microsatellite analysis (not shown). Fecal
RNA was extracted and subjected to RT-PCR analysis using
consensus sequence- as well as strain-specific primers (see Ta-
ble S1 in the supplemental material). For CP684, CP2135, and
CP2139, this approach yielded 12 to 15 partially overlapping
fragments, which in each case spanned an entire provirus (Fig.
2A). Amplification of SIVgor sequences from sample BQ664
was more difficult. Despite repeated RT-PCR attempts and
multiple primer combinations, only two new fragments in gag
and the accessory gene region could be amplified (Fig. 2A). All
amplicons were sequenced directly to generate fecal consensus
sequences. As expected, these contained a limited number of
ambiguous sites, including base mixtures and sequence differ-
ences in regions of fragment overlap (see Table S2 in the
supplemental material). Although some of the ambiguous sites
affected the encoded amino acid, none introduced stop codons
or frameshift mutations.
The concatenated genomes of CP2139, CP2135, and CP684
were 9,252, 9,246, and 9,143 nucleotides in length, respectively.
All three carried full-length open reading frames for all nine
genes found in SIVcpz/HIV-1 (Fig. 2A) as well as all major
regulatory sequences. Although the deduced SIVgor, SIVcpz,
and HIV-1 protein sequences varied considerably, we found no
obvious SIVgor-specific signatures. For example, all three
gorilla viruses encoded additional cysteine residues in their
fourth variable (V4) envelope domain (two in CP2139 and four
in CP2135 and CP684), indicating a more diversified V4 loop
structure; however, this was not unique to SIVgor, since addi-
tional cysteine residues (usually two) were also observed in the
V4 domain of HIV-1 group O and some SIVcpz strains (not
shown). Similarly, SIVgor Vpu sequences differed from those
of SIVcpz and HIV-1 (including group O) in more than 60% of
amino acid residues; however, the predicted secondary struc-
ture and hydrophobicity profiles of the deduced SIVgor Vpu
proteins suggested a very similar function (not shown). Inter-
estingly, there were some protein domains where SIVgor
strains resembled chimpanzee and not human viruses. At po-
sition 30 of the Gag matrix protein, the three gorilla viruses
(like all strains of SIVcpzPtt) encoded a methionine rather
than the arginine found in the ancestors of HIV-1 groups M,
N, and O (75). Similarly, in a phenogram of V3 loop se-
quences, all gorilla viruses clustered with SIVcpz strains (Fig.
3), rather than grouping with HIV-1 group O viruses to which
they are much more closely related (see below). Thus, at two
sites known to be under host-specific selection pressures in
humans and chimpanzees (70, 75), SIVgor resembled SIVcpz
rather than HIV-1.
Origin of SIVgor. To compare the evolutionary relationships
of the newly derived gorilla viruses to each other and to pre-
viously characterized SIVcpz and HIV-1 strains, phylogenetic
trees were constructed from different regions of the proteome.
For the fully sequenced CP2139, CP2135, and CP684 strains,
these included Gag, the N-terminal half of Pol (Pol1), the
C-terminal half of Pol plus Vif (Pol2), and Env (Fig. 4). For the
partially characterized BQ664 strain, individual Gag, Pol, Vif-
Env, and gp41 fragments were concatenated prior to analysis
(Fig. 5). These studies confirmed and extended previous results
from subgenomic SIVgor sequences (71). In all regions of their
genome, the gorilla viruses clustered in a monophyletic clade
that was most closely related to HIV-1 group O viruses. Within
the SIVgor lineage, strains from the CP field site were much
more closely related to one another than they were to BQ664.
The branching orders of the three CP strains varied among
trees from different parts of the genome, but these relation-
ships were not significantly discordant, and closer examination
of the nucleotide alignments of the CP strain sequences (using
GENECONV) detected no evidence for recombination. Fi-
nally, the SIVgor/HIV-1 group O clade was significantly more
closely related to SIVcpzPtt from central chimpanzees than to
SIVcpzPts from eastern chimpanzees, strongly suggesting a
west central African origin for SIVgor.
The phylogenetic relationships in Fig. 4 were derived from
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large genomic regions, and so, to check for any evidence of
recombination involving smaller fragments, we made numer-
ous trees based on shorter (300 amino acids) windows from the
alignments. This analysis identified a 900-bp region at the 5
end of the pol gene that appeared to have a different evolu-
tionary history. While a tree derived from Pol sites 301 to 699
(from a gap-stripped Pol alignment) exhibited the conven-
tional topology with SIVgor and HIV-1 group O viruses clus-
tering exclusive of SIVcpzPtt strains and other HIV-1 groups
(Fig. 6, right), in a tree of N-terminal Pol sequences (sites 1 to
300), this was no longer true (Fig. 6, left). Support for this
discordant branching was high: the grouping of the SIVcpzPtt
strains MT145 and GAB2 together with SIVgor/group O out-
side the remaining SIVcpzPtt strains had a posterior probabil-
ity value of 98%. These results indicated that recombination
had occurred during the divergence of these sequences.
Two different evolutionary scenarios could explain the dis-
cordant branching orders in Fig. 6. One possibility is that an
ancestor of SIVgor acquired sequences from an ancestral
SIVcpzPtt strain; in this case, SIVgor is recombinant. Alterna-
tively, an ancestor of MT145 and GAB2 could have acquired
sequences from a divergent SIVcpzPtt lineage that has not yet
been sampled or is now extinct; in this case, MT145 and GAB2
are recombinant. To distinguish between these scenarios, we
compared the divergences of the various strains in recombi-
nant and nonrecombinant regions. Under the first scenario, the
SIVgor/group O lineage would be expected to change its po-
sition in the two trees, i.e., this lineage would move inside the
SIVcpzPtt clade. As a result, the common ancestor of the
entire SIVcpzPtt/SIVgor/HIV-1 clade in the recombinant re-
gion (the red node in Fig. 6) would be equivalent, in terms of
distance from the root or the tips of the tree, to the ancestor of
the SIVcpzPtt/HIV-1 clade in the nonrecombinant region (the
blue node in Fig. 6). Alternatively, if MT145 and GAB2 were
recombinant, the red node would be equivalent to the ancestor
of the entire SIVcpzPtt/SIVgor/HIV-1 clade in the nonrecom-
binant region (the green node in Fig. 6). To evaluate these
alternative hypotheses, we calculated the evolutionary dis-
tances from each of these highlighted nodes to the tips of the
four strains in the SIVcpzPts clade (Table 1). All distances
were measured as average branch lengths, and this was done
independently for Gag (Fig. 4) as well as the recombinant (Fig.
6, left) and nonrecombinant (Fig. 6, right) portions of Pol. In
order to correct for different rates of evolution in different
proteins, each distance was divided by the total length of the
tree for that genomic region. Finally, all HIV-1 strains and one
SIVcpzPtt recombinant (LB7) were excluded. The results
showed that the distance for Pol sites 1 to 300 (for the red
node) was similar to those for the green node (and lower than
those for the blue node) for Gag and Pol sites 301 to 699
(Table 1), indicating that SIVcpzPtt strains MT145 and GAB2
were recombinant. Although these two SIVcpzPtt strains did
not form a statistically supported clade in the recombinant
region (Fig. 6, left), the shared mosaicism implied that they
were monophyletic. This finding was also supported by results
from an analysis of internal branch lengths (not shown) and is
consistent with our previous conclusion that GAB2 is recom-
binant and contains pol gene sequences from a divergent
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FIG. 3. V3 loop diversity among different ape lentiviruses. The phenetic clustering of SIVgor (red), SIVcpz (black), and HIV-1 (blue) V3 amino
acid sequences is shown. Four major V3 clusters are apparent: (i) HIV-1 group M, (ii) the MB/LB strains of SIVcpz, (iii) all other SIVcpz strains
(except GAB2) plus HIV-1 group N and SIVgor, and (iv) HIV-1 group O. Dashes indicate gaps introduced for better alignment.
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SIVcpzPtt strain (11). Since it is clearly most parsimonious to
assume that the recombination event in the ancestry of MT145
and GAB2 occurred during infection of a central chimpanzee,
this implies that SIVgor and HIV-1 group O viruses are de-
rived from a divergent SIVcpzPtt lineage that existed (and
possibly still exists) in west central Africa.
Chimpanzee and gorilla viruses from the same field site.
The finding of divergent SIVgor strains at two field sites
located 400 km apart (CP and BQ) (Fig. 1) suggested that
wild-living gorillas are endemically infected with SIVgor
(71). However, the possibility that local chimpanzee-to-go-
rilla transmissions had generated the observed SIVgor di-
versity could not be formally excluded. To examine whether
neighboring ape communities harbored epidemiologically
linked viruses, we specifically targeted wild-living chimpanzees
in one area of high gorilla density (39). Screening 77 chimpan-
zee fecal samples from the CP field site, we found 9 to be
SIVcpz antibody positive. These were identified to represent
two naturally infected P. t. troglodytes apes (CP1973 and
CP2680) that were sampled 8 months apart. Although the
results for initial RT-PCR analyses were negative for diagnos-
tic pol and gp41 regions (33, 70), most likely because of sample
degradation, a small, 220-bp pol fragment was eventually am-
plified. Phylogenetic analysis of the resulting sequences con-
firmed that the two chimpanzees were infected with distinct
SIVcpzPtt strains which were only distantly related to SIVgor
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FIG. 4. Evolutionary relationships of newly derived SIVgor strains. Trees were inferred for four proteomic regions (Gag, Pol1, Pol2, and Env),
where Pol1 ends at a recombination breakpoint previously identified in HIV-1 group N, and Pol2 includes downstream Vif sequences. The SIVgor
sequences (red) were compared to representatives of SIVcpz (black) and HIV-1 (blue) groups M (U455 and LAI), N (YBF30 and YBF106), and
O (ANT70 and MVP5180). The four lowest SIVcpz strains (ANT, TAN1, TAN2, and TAN3) are from eastern chimpanzees; all others are from
central chimpanzees. Numbers on internal branches indicate estimated posterior probabilities (only values above 95% are shown). The scale bars
represent 0.05 (or 0.1 for Env) amino acid replacements per site.
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strains identified in the same geographic area (Fig. 7). While
we have analyzed only two chimpanzees from the CP site,
previous surveys have shown that SIVcpzPtt strains exhibit
strong phylogeographic clustering (33, 70). The distant rela-
tionship between the chimpanzee and gorilla viruses from CP
thus indicates that these SIVgor strains were not due to a local
transmission from chimpanzees. Furthermore, all SIVgor
strains form a single cluster, strongly suggesting that they all
descended from the same chimpanzee-to-gorilla transmission.
Thus, the diversity within the SIVgor clade most likely reflects
viral evolution in gorillas.
Timing of the MRCA of SIVgor. The results described above
suggest that all currently known SIVgor strains are derived
from a single introduction of SIVcpzPtt into western lowland
gorillas. To gauge when this introduction might have occurred,
we estimated the time to the MRCA of the SIVgor clade. It is
not yet possible to obtain a reliable estimate of the rate of
SIVgor evolution, because only a few strains have thus far been
characterized, and all were isolated within a narrow time pe-
riod (2004 to 2007). We therefore used an evolutionary rate
estimated from closely related HIV-1 group O strains. A phy-
logeny was obtained from a nucleotide sequence alignment
produced by concatenating the four genomic regions available
for BQ664, and distances between sequences were calculated
by summing branch lengths from that tree. The average esti-
mated distance between BQ664 and the CP strains was 0.295
substitutions per site. The year of the MRCA of HIV-1 group
O has been estimated as 1920, with a confidence (95% highest
posterior density) interval of 1896 to 1942 (35). With these
dates, the rate of nucleotide substitution for HIV-1 group O
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TABLE 1. Genetic distances within the SIVcpz/SIVgor/HIV-1 radiation
Node
Distancea
Gag Pol sites1–300
Pol sites
301–699
Blue 0.27 0.26
Green 0.22 0.24
Red 0.22
a Distances were calculated as average branch lengths from the tips of each of
the four SIVcpzPts strains to the relevant nodes depicted in Fig. 6.
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for the genomic regions used here was estimated to be 1.05 
103 (range, 0.79  103 to 1.50  103) per site per year.
Then, assuming that SIVgor strains have evolved at the same
rate as group O viruses, their MRCA was estimated to have
existed around 1864 (range, 1818 to 1906). Thus, the chimpan-
zee-to-gorilla transmission that spawned the current SIVgor
infections seems to have occurred at least 100 to 200 years ago.
Generation and biological characterization of a replication-
competent SIVgor clone. We have previously shown that rep-
lication-competent molecular clones of SIVcpz can be derived
from fecal viral consensus sequences (65). However, for this
strategy to be successful, we found that it was critical to amplify
the most predominant viral species in the fecal sample. To
ensure that this was the case for SIVgor, we selected one of the
three fully sequenced SIVgor strains (CP2139) and reamplified
its entire genome by using reextracted fecal RNA as well as
strain-specific primers (Fig. 2B). As expected, the second con-
sensus sequence (CP2139.2) was not identical to the first
(CP2139.1); there were 54 nucleotide sequence differences, the
majority of which were located in the env gene. Table S3 in the
supplemental material lists all sequence differences between
CP2139.1 and CP2139.2 and indicates which nucleotides were
selected for inclusion in the molecular clone.
The CP2139 master sequence was used as the template to
chemically synthesize three subgenomic fragments. These were
then ligated into a low-copy-number (pBR322-derived) plas-
mid to generate the proviral clone CP2139.287 (Fig. 2B). To
examine its biological activity, CP2139.287 was transfected into
293T cells and the resulting supernatant tested for infectivity in
the JC53-BL cell assay. This analysis showed that CP2139.287-
derived virus was infectious (600 to 800 IU/ng reverse trans-
criptase) and entered JC53 cells via the CCR5 coreceptor. As
shown in Fig. 8, infectivity of CP2139.287 was completely
blocked by the CCR5 antagonist TAK-779 but not by the
CXCR4 antagonist AMD3100. This was also true for the pri-
mary HIV-1 strains YU-2 (group M), YBF30 (group N), and
97US08692A (group O) but not for NL4-3- and WEAU 1.6-
derived viruses, which served as X4 and R5/X4 dual tropic
FIG. 9. Replication potential of SIVgor in human and chimpanzee
CD4 T cells. The replication kinetics of CP2139.287-derived virus in
human (A) and chimpanzee (B) CD4 T cells are shown in relation to
those of HIV-1 (SG3, YU2), SIVcpzPtt (MT145, MB897, EK505, and
GAB2), and SIVcpzPts (TAN1, TAN2, and TAN3) reference strains (x
axis, number of days postinfection; y axis, nanograms of reverse trans-
criptase [RT] activity per ml of culture supernatant). Similar replica-
tion kinetics were observed for CP2139.287-derived virus in CD4 T
cells from three additional human and two additional chimpanzee
donors.
FIG. 7. Evolutionary relationships of SIVgor and SIVcpz strains
infecting gorillas and chimpanzees at the CP field site. A tree was
inferred for a diagnostic Pol fragment (220 bp). Two SIVcpzPtt strains
from the CP field site are boxed. The other strains are color coded as
in Fig. 4. Numbers on internal branches indicate estimated posterior
probabilities (only values above 95% are shown). The scale bars rep-
resent 0.1 replacements per site.
FIG. 8. Coreceptor usage of SIVgor. JC53-BL cells were pre-
treated with AMD3100 (inhibitor of CXCR4), TAK779 (inhibitor of
CCR5), or both prior to addition of the virus preparations indicated.
Virus infectivity is plotted on the vertical axis as a percentage of the
untreated control. Virus derived from the replication-competent mo-
lecular clones NL4.3 (X4-tropic), YU2C (R5-tropic), and WEAU1.6
(dual tropic) as well as the primary isolates 97US08692A (group O)
and YBF30 (group N) were included for control.
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controls, respectively (Fig. 8). Culture experiments also showed
that CP2139.287-derived virus replicated efficiently and to high
titers in both human and chimpanzee CD4 T cells, with ki-
netics very similar to those of previously characterized SIVcpz
and HIV-1 strains (Fig. 9). Taken together, these data dem-
onstrated that the reconstructed CP2139.287 clone carried a
fully functional, replication-competent SIVgor genome.
To examine the antigenic properties of SIVgor, we tested
CP2139.287-derived virus as well as a panel of HIV-1 group M
(NL4-3 and YU-2), N (YBF30), and O (97US08692A) viruses
for their sensitivity to anti-HIV-1 monoclonal and polyclonal
antibodies as well as receptor and fusion inhibitors (Table 2).
These experiments showed that SIVgor was resistant to neu-
tralization by monoclonal antibodies directed against the CD4
binding site (b12), surface glycans (2G12), and membrane-
proximal external region (4E10 and Z13e1). SIVgor was also
resistant to neutralization by monoclonal antibodies directed
against the coreceptor binding site (17b, 21c, and 19e) and the
V3 loop (447-52D and F425-B4e8) of HIV-1 in the presence
and absence of soluble CD4, highly reactive subtype B and C
plasma pools, and two group O plasma samples. In contrast,
SIVgor was highly sensitive to the fusion inhibitors T-20 and
T-1249 (IC50s of 0.001 g/ml and 0.004 g/ml, respectively)
and to the membrane-proximal external region monoclonal
antibody 2F5 (IC50, 4.6 g/ml). The infectivity of CP2139.287-
derived virus was also blocked by a monoclonal antibody di-
rected against cell surface-expressed CD4 (IC50, 0.23 g/ml),
indicating that access to this receptor was required for SIVgor
cell entry. Interestingly, the latter was not the case for the
group O virus 97US08692A, which was completely resistant to
this antibody (IC50, 2 g/ml). 97US08692A was also moder-
ately sensitive to the V3 monoclonal antibody 447-52 (despite
its divergent V3 crown sequence) (Fig. 3), suggesting a some-
what exposed V3 loop. These data suggest that 97US08692A
may be relatively CD4 independent. Future experiments will
need to determine whether this property is unique to
97US08692A or general in HIV-1 group O viruses.
DISCUSSION
A primary objective of this study was to determine the origin
of SIVgor and to estimate where and when this virus might
have been introduced into wild-living gorillas. By sequencing
three new full-length SIVgor genomes and conducting detailed
recombination analyses, we found evidence for an ancestral
SIVcpzPtt lineage from which SIVgor and HIV-1 group O
viruses evolved (Fig. 6). Although full-length representatives
of this lineage were not identified, we documented its existence
in the form of mosaic pol fragments in present-day SIVcpzPtt
recombinants. This finding strongly suggests that P. t. troglo-
dytes apes were the original source of SIVgor and that the
cross-species transmission took place in the Cameroon/Equa-
torial Guinea/Gabon area of west central Africa (Fig. 1). To
estimate when this event might have occurred, we calculated
the time to the MRCA of the current SIVgor clade. This
analysis yielded an estimate of 100 to 200 years for the diver-
gence of BQ664 from the three other SIVgor strains (Fig. 5).
The transmission that gave rise to SIVgor likely occurred much
earlier than that since (i) currently available SIVgor sequences
may not represent the entire diversity of extant gorilla viruses,
(ii) SIVgor strains that diverged earlier may have gone extinct,
and (iii) phylogenetic methods are notorious for underestimat-
ing the deeper divergence times of rapidly evolving RNA vi-
ruses (31, 56). Once introduced, SIVgor spread within its new
host, as evidenced by the presence of viruses at field sites
located 400 km apart (Fig. 1). Whether this occurred primarily
by sexual or other (e.g., exposure to infectious saliva) routes is
not known; however, it is likely that gorilla behavior and social
structure facilitated virus dispersal. Western lowland gorillas
live in family units of 2 to 30 individuals which typically com-
prise one dominant male (silverback), three or more sexually
active adult females, their offspring, and possibly a few non-
dominant males (27, 42, 62, 67). The silverback mates with all
adult females in the group (27, 48). Adolescent males typically
leave their natal groups and become solitary (and highly mo-
bile) until they form their own harems (23), while females also
transfer between groups (63). Individual groups have home
ranges of about 15 to 20 km2 (8, 22, 47), which often overlap,
resulting in frequent encounters of neighboring groups (8, 17,
22, 67). Thus, gorilla mating and social networks provide ample
opportunity for a newly introduced SIV to spread, both within
and between neighboring communities.
As illustrated in Fig. 4, chimpanzees have transmitted
SIVcpz to gorillas and humans on multiple occasions. For
humans, exposure to infected chimpanzee blood or mucosal
TABLE 2. Neutralization phenotype of SIVgor
Virusb
Neutralization titera
sCD4
(nM) HIVIG
c Clade B
plasma pool
Clade C
plasma pool
Group O
plasma
Group O
plasma b12 2G12 2F5 4E10 Z13e1 T-20 T-1249
SIVgor
(CP2139.287)
154 1000 20 	20 	20 	20 50 50 4.6 50 50 0.001 0.004
HIV-1_O
(97US08692A)
21 1000 NAd NA NA NA 50 50 50 50 50 0.010 0.084
HIV-1_N (YBF30) 498 1000 	20 	20 	20 	20 50 50 50 34.63 50 0.016 0.026
HIV-1_M (NL4.3) 2 71 630 358 83 	20 0.01 0.85 0.44 1.35 50 0.102 0.001
HIV-1_M (YU2) 14 891 178 267 	20 	20 1.63 50 50 50 50 0.143 0.044
a Neutralization titers are expressed as the reciprocal 50% inhibitory plasma dilutions or the IC50s for the respective Env ligands in one representative experiment
(performed in duplicate). All titers are given in g/ml unless otherwise stated.
b CP2139.287, NL4.3, and YU2 are molecular clones of HIV-1 strains. 97US08692A and YBF30 are primary HIV-1 isolates.
c HIVIG, pooled human immunoglobulin purified from plasma samples of healthy HIV-1-infected individuals.
d NA, not available.
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secretions in the context of bushmeat hunting is considered the
most plausible scenario for cross-species transmission (30). For
gorillas, the route and circumstances of transmission are much
less clear. Gorillas are herbivores and do not hunt other mam-
mals (41, 49, 68). However, recent studies have shown that
gorillas and chimpanzees commonly feed in the same forest
areas and sometimes even in the same fruiting trees (76). Thus,
there are focal points for gorilla/chimpanzee encounters that
may facilitate virus transmission. Moreover, SIV is not the only
virus requiring physical contact for infection that has crossed
the species barrier from chimpanzees to gorillas: screening ape
fecal samples for hepatitis B virus DNA, we found that this
pathogen has been transmitted from wild-living chimpanzees
to gorillas on at least two occasions (W. Liu and B. H. Hahn,
unpublished). Since hepatitis B virus, like HIV/SIV, is trans-
mitted by direct contact with infectious blood or mucosal se-
cretions (25), encounters between chimpanzees and gorillas
that are conducive to cross-species infection must occur.
Whether these are physical in nature (i.e., fighting or biting),
involve exposure to infectious feces or urine in cofeeding areas,
or occur through saliva in partially eaten, discarded fruit (76)
will need to be determined. Whatever the circumstances, it
appears that successful transmission events are rare.
While it seems clear that chimpanzees were the source of
SIVgor, it is not known whether humans acquired HIV-1
group O from naturally infected chimpanzees or gorillas. Thus
far, none of the chimpanzee and gorilla communities tested
represent likely reservoirs. The known SIVgor strains are too
divergent to have been the immediate source of HIV-1 group
O (Fig. 4). In addition, the prevalence of SIVgor infection in
Cameroon is very low (C. Neel and M. Peeters, unpublished).
Finally, none of several hundred P. t. troglodytes apes tested in
southern Cameroon, including those at the CP field site (Fig.
8), harbor SIVgor-like viruses (33, 70). Together, these data
strongly suggest that the ape reservoir that gave rise to HIV-1
group O exists outside Cameroon. It will be important to
determine whether this reservoir still exists and, if so, where it
is located. Moreover, it will be important to differentiate be-
tween different transmission scenarios (Fig. 10). One possibil-
ity is that chimpanzees harboring SIVgor-like viruses infected
gorillas and humans independently; identification of SIVcpzPtt
strains that join either the branch outside the HIV-1 group O
or that outside the SIVgor clade would provide strong support
for such a scenario (green lines in Fig. 10A). Alternatively,
gorillas may have served as an intermediary host for the human
infection; evidence for this would come from the finding of
SIVgor strains that join either the branch outside group O or
that outside the entire HIV-1 group O/SIVgor clade (Fig.
10B). The viruses invoked in either of these scenarios may exist
in as-yet-unsampled apes in Equatorial Guinea, Gabon, or the
Republic of the Congo. Indeed, the relative prevalence of
group O infections has been reported to be much higher in
Equatorial Guinea (9% of HIV-1 infections) than in Cam-
eroon (2% of HIV-1 infections), pointing to this area as a
possible starting point of the HIV-1 group O epidemic (3, 15,
43, 74, 80). Formally, there is a third possibility, namely, that
chimpanzees harboring SIVgor-like viruses first infected hu-
mans, who then passed the virus to gorillas. However, this
would imply that HIV-1 group O was far more divergent in the
past than is currently the case (Fig. 10C). Moreover, it is hard
TABLE 2—Continued
Neutralization titera
Coreceptor
used447-52D 447-52DsCD4
F425-
B4e8
F425-B4e8
sCD4 17b
17b
sCD4 19e 19e sCD4 21c 21c sCD4
Anti-CD4
MAb
TAK-779
(M)
25 25 25 25 10 10 10 10 10 10 0.23 0.033 R5
12.47 25 25 25 10 10 10 10 10 10 2 0.201 R5
25 25 25 25 10 10 10 10 10 10 0.19 0.034 R5
0.02 0.01 25 25 0.17 0.26 10 10 0.55 1.1 1.89 10 X4
10.24 0.02 25 1.68 10 10 10 10 10 10 0.17 0.007 R5
FIG. 10. Possible scenarios for the origin of HIV-1 group O. (A) Chimpanzees harboring SIVgor-like viruses infected gorillas and humans
independently. (B) Chimpanzees harboring SIVgor-like viruses infected gorillas, which then passed the virus on to humans. (C) Chimpanzees
harboring SIVgor-like viruses infected humans, who then passed the virus to gorillas. Support for each scenario would come from the discovery
of one of the hypothetical viruses shown in green. In all three trees, nodes marked by circles indicate ancestral viruses that are assumed to have
infected chimpanzees.
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to imagine how humans could transmit a virus such as SIVgor
to wild-living gorillas. Thus, the third scenario is implausible.
A second objective of this study was to generate a repli-
cation-competent molecular clone of SIVgor for biological
analyses. We accomplished this by synthesizing the complete
genome of one of the newly characterized gorilla viruses
(CP2139) from fecal consensus sequences. The availability of
this SIVgor clone allowed us to compare its baseline biological
properties to those of SIVcpz and HIV-1 reference strains. As
shown in Fig. 9, SIVgor replicated to high titers in CD4 T
cells from human (n 
 4) and chimpanzee (n 
 3) donors. We
also assessed the sensitivities of SIVgor to a number of Env-
specific ligands (Table 2). The results revealed that SIVgor
used both CD4 and CCR5 receptors for cell entry (Fig. 8).
SIVgor was sensitive to neutralization by the membrane-prox-
imal external region monoclonal antibody 2F5, consistent with
the conservation of the epitope recognized (ALLELDKW
AD). SIVgor was also highly sensitive to the two fusion inhib-
itors T20 and T1249 (Table 2), possibly because of a glu-
tamine-to-arginine substitution at position 580 (position 577 in
HXB2). The glutamine at position 577 in HXB2 is believed to
interact with a tryptophan at position 628 (position 634 in
CP2139), and the observed arginine substitution would be ex-
pected to destabilize the formation of the gp41 six-helix bundle
(Bing Chen, personal communication). In contrast, SIVgor was
resistant to neutralization by monoclonal antibodies b12,
2G12, 4E10, and Z13e1, most likely due to epitope variation.
SIVgor was also completely resistant to CD4i (17b, 21c, and
19e) antibodies, both in the absence and in the presence of
sCD4. Since the coreceptor binding surface is highly conserved
between diverse HIV-1 and HIV-2 strains (19), these data
strongly suggest that the SIVgor CD4i bridging sheet is
shielded as it is in primary strains of HIV-1. SIVgor was also
resistant to the V3 monoclonal antibodies 447-52D and F425-
B4e8, both of which recognize a highly conserved arginine
residue at position 315 in the V3 loop crown (GPGR) (7, 59).
Since the crown of the SIVgor V3 loop (GPMT) lacks such an
arginine, it is possible that these antibodies failed to neutralize
the viruses because of epitope variation. However, the acces-
sibility of V3 to antibodies has been shown to have a major
impact on V3-mediated neutralization. The fact that an HIV-1
group O strain (97US08692A) that encodes a similarly diver-
gent V3 crown (GPLA) was resistant to entry inhibition by a
monoclonal antibody against surface CD4 and was moderately
sensitive to 447-52D (Table 2) suggests that the SIVgor V3
loop, like its CD4i bridging sheet, may be concealed in the
functional Env trimer. Finally, we found that SIVgor was re-
sistant to neutralization by heterologous patient antibodies,
including two group O plasmas. Altogether, these findings sug-
gest that the sensitivity of SIVgor to Env-specific ligands re-
sembles that of primary HIV-1 and SIVcpz strains in several
ways, including those related to CD4 tropism, CCR5 corecep-
tor preference, and effective concealment of CD4i (and possi-
bly also V3 epitopes) in the functional Env trimer.
Given the biological properties of SIVgor and the extent of
ape bushmeat hunting in west central Africa (14, 39, 69), it is
clear that wild-living gorillas could represent a reservoir for
human infection. Additional field studies are thus needed to
determine the prevalence, geographic distribution, species as-
sociation, and natural history of SIVgor throughout the entire
gorilla habitat. Given the current rate of deforestation in cen-
tral Africa and the extent of bushmeat hunting and consump-
tion, it is critical to collect baseline data on existing sources of
human zoonotic diseases now. This approach has been success-
ful for Ebola hemorrhagic fever (36), monkeypox (46), and
anthrax (34). Continuation of noninvasive surveys of wild ape
populations is thus critical, not only to identify the primate
origin of HIV-1 group O but also to ensure that additional
reservoirs of HIVs are not overlooked.
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